skip to main content

Acral Melanoma — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardMelanoma & SkinAcral MelanomaSCE Medical Oncology

A 16-year-old with untreated unresectable BRAF-wild-type melanoma is being considered for nivolumab-relatlimab. Which funding and duration statement matches NICE TA950?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — It is an option from age 12 and is stopped after 2 years or earlier if disease progresses

Option D is correct: TA950 covers untreated advanced melanoma from age 12 and uses a 2-year maximum, or earlier stopping on progression. Option E has the wrong age and duration. Option A invents a PD-L1 threshold. Option B places it in the wrong line, and option C invents a 6-month cap.

Reference: NICE TA950: nivolumab-relatlimab in untreated advanced melanoma. https://www.nice.org.uk/guidance/TA950/chapter/1-Recommendations